

Chordate Medical launches Ozilia migraine and rhinitis treatment in the United Arab Emirates

Chordate Medical ("Chordate," "the company") has contracted MEDSWAN MEDICAL SUPPLIES L.L.C, Dubai, as a market expert in the United Arab Emirates (UAE) for the introduction of the company's product Ozilia to the UAE market. As previously announced, the company intends to explore opportunities in the broader Gulf region based on the successes and experiences gained in Saudi Arabia, making the move into the UAE market a logical next step.

Medswan is owned and led by Hanna Hardwick, a Swedish Arabic-speaking businesswoman with 20 years of experience in leading sales and marketing positions within the medtech and pharma sectors in the MEA region. She has worked for global companies such as Sirtex, Terumo, Fresenius, Hilrom, and Siemens.

"Based on several important customer contacts for the UAE that we have collected at recent international congresses, we are expanding our focus primarily on chronic migraine in the Gulf region. Medswan will now register the products, a process estimated to take ten weeks, and concurrently launch and create market access for Ozilia. Hanna Hardwick has extensive experience in relevant specialist segments within medtech, a strong familiarity with market introductions, and a broad network," says Anders Weilandt, CEO of Chordate.

"The healthcare market in the UAE is almost entirely private and relatively straightforward to access. In recent days, we have visited four leading neurologists at as many hospitals here in Dubai – there is no doubt that Ozilia is a drug-free alternative that doctors here see a significant need to have access to."

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
28 November 2023 08:30:00 CET

CHORDATE
M E D I C A L

Attachments

[Chordate Medical launches Ozilia migraine and rhinitis treatment in the United Arab Emirates](#)